{"id":386838,"date":"2020-11-23T09:03:36","date_gmt":"2020-11-23T14:03:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386838"},"modified":"2020-11-23T09:03:36","modified_gmt":"2020-11-23T14:03:36","slug":"parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/","title":{"rendered":"Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON and DURHAM, N.C., Nov.  23, 2020  (GLOBE NEWSWIRE) &#8212; Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced a strategic partnership between its Early Phase Clinical Unit (EPCU) in Berlin, Germany and Clinical Trial Center (CTC) North, a full-service CRO located at the University Medical Center Hamburg-Eppendorf (UKE).<\/p>\n<p>The strategic collaboration supports the high demand for and continuation of Early Phase clinical studies during the COVID-19 pandemic, enabling the optimal use of resources and providing additional bed capacity for healthy volunteers and patients ensuring early phase research can continue. One central point of the collaboration will be the roll-out and implementation of Parexel\u2019s eSource system ClinBase<sup>TM<\/sup> at CTC North to drive efficiency and collaboration.<\/p>\n<p>\u201cWe\u2019re delighted about the CTC North partnership, which leverages broad expertise across both partners to provide a unique solution for Clinical Pharmacology research in healthy volunteers and patients,\u201d said Dr. Sandra Stark, Head of the Berlin EPCU &amp; Interim Head, Global EPCUs. \u201cThe use of ClinBase as the eSource system will support trials from a data perspective resulting in minimal timelines for post-clinical services.\u201d<\/p>\n<p>Multiple ongoing and recently awarded studies are being conducted at CTC North as well as biosimilar, COVID-19, food effect and bioavailability studies, among others. CTC North and its Clinical Pharmacology Unit have partnered with UKE for more than 10 years, primarily in the conduct of vaccine development and first-in-human trials.<\/p>\n<p>\u201cWe\u2019re pleased to have the opportunity to partner with Parexel\u2019s Berlin EPCU after collaborating together for many years,\u201d said Ralf Freese, Medical Director and Vice President of BVMA (Federal Association of Contract Research Organizations). \u201cUnder one roof, we\u2019re combining Parexel\u2019s \u2018excellence\u2019 with CTC North\u2019s access to one of Europe\u00b4s most modern clinics at UKE providing access to specialists from all fields of medicine.\u201d<\/p>\n<p>In addition to its Berlin EPCU, Parexel\u2019s Early Phase clinical development presence includes EPCUs in Baltimore and Los Angeles (USA) and London (United Kingdom), providing access to more than 300 beds and 35+ patient populations. This global network enables customers to run Phase I trials from multiple locations simultaneously with integrated technology to make decisions in real-time. During the COVID-19 pandemic, Parexel has adapted its Early Phase facilities and processes to mitigate viral transmission risks. Each of the company\u2019s units can support COVID-19- related product development and flexible\u00a0capacity models and decentralized clinical trial processes\u00a0have been introduced where possible to help advance Early Phase programs in support of COVID-19 therapies.<\/p>\n<p>\n        <strong>About Parexel<\/strong><br \/>\n        <br \/>Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life science and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned <br \/>by a deep conviction in what we do.\u00a0For more information, visit our\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eJ37QCvpwriGdIxsq7Rku18u0HiMRX-VwyiU268QjYro97v-3PGxAwRrshcyQKgB1pNRgE9i5G0_lJJU9C1haw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>website<\/strong><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2QbTEq_my9S_PKizeye61bo1BLH1sRK4YfI0gL6wquuiO71GsdoHLGy2MtBvfu0FPbYsKkvLoUXqRBxb536MFOXzNUlgWPjsQtF6pfA2Ws8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=enBExiqk3elJCdBvZ1Kx27_HNKHy0_wZZWvsWKJABNaJTv-ohKAtiddYKpN1YyVXBJteHl2bhbLuwuOnwOD3-3SBVv6e8JFJaItPpDgVNvU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>Twitter<\/strong><\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mZoLAf93i3Hli7KgLHUPnIJf0cq0NFmS-R4z3BqDyIcpRBoe3BMgdK4yr0NPvBzD7qI96SgH_MoUnA5FATjrQAlOh6Mo3SEILtr9cQRgljI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>Instagram<\/strong><\/a>.<\/p>\n<p>\n        <strong>About <\/strong><br \/>\n        <strong>CTC North<\/strong><br \/>\n        <br \/>CTC North is an independent full-service CRO located at the University Medical Center Hamburg-Eppendorf (UKE). Its objective is to guarantee the professional conduct of clinical trials in accordance with ICH-GCP, the German Drug Law (AMG) and the German Medical Device Law (MPG) within a university environment. CTC North provides professional services in all aspects of clinical trials and offers complete clinical trial management complying with regulatory guidelines valid worldwide and the highest quality assurance standards. It acts as an advisor to investigators and scientists and provides a variety of support services related to conducting clinical trials. CTC North has extensive experience with the coordination of multicenter clinical trials, with a focus on studies with non-commercial sponsors (IITs). The following services are provided: Project management, regulatory services, medical writing, safety monitoring, monitoring, data management, and statistics.<\/p>\n<p>\n        <strong>CONTACT: <\/strong>\n      <\/p>\n<p>\n        <strong>Parexel <\/strong><br \/>\n        <br \/>Lori Dorer<br \/>+1 978 495 4135 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JWcM2GHV3Icj0P3XPcOfFTA-UfilaI3KJeNwDMgelEt-P5Ptxq8w677Ydj0-DMp1oJ8K-YuGBD7_ENf0rMDx4gddNS3FSnCxm2z12xQN72A=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">lori.dorer@parexel.com<\/a><\/p>\n<p>\n        <strong>W2O<\/strong><br \/>\n        <br \/>Lindsay LeCain<br \/>+1 508 259 9521<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ABEKoT_PqWH_A0lFCk-yIVGj7fiksuWdxz077uWhmmNALH8HevACeCD9JIQjB9BydYTfLFRwiLf7Hr3EGslcCUh3bs5CeucFfZq5hvXNoO8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">parexelpr@w2ogroup.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEzNiMzODM4MTg3IzIwMDg1OTY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/301e1a9b-d7c4-4530-9ea7-1ff1f15d8324\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON and DURHAM, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced a strategic partnership between its Early Phase Clinical Unit (EPCU) in Berlin, Germany and Clinical Trial Center (CTC) North, a full-service CRO located at the University Medical Center Hamburg-Eppendorf (UKE). The strategic collaboration supports the high demand for and continuation of Early Phase clinical studies during the COVID-19 pandemic, enabling the optimal use of resources and providing additional bed capacity for healthy volunteers and patients ensuring early phase research can continue. One central point of the collaboration will be the roll-out and implementation of Parexel\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386838","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON and DURHAM, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced a strategic partnership between its Early Phase Clinical Unit (EPCU) in Berlin, Germany and Clinical Trial Center (CTC) North, a full-service CRO located at the University Medical Center Hamburg-Eppendorf (UKE). The strategic collaboration supports the high demand for and continuation of Early Phase clinical studies during the COVID-19 pandemic, enabling the optimal use of resources and providing additional bed capacity for healthy volunteers and patients ensuring early phase research can continue. One central point of the collaboration will be the roll-out and implementation of Parexel\u2019s &hellip; Continue reading &quot;Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T14:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEzNiMzODM4MTg3IzIwMDg1OTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials\",\"datePublished\":\"2020-11-23T14:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/\"},\"wordCount\":672,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDEzNiMzODM4MTg3IzIwMDg1OTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/\",\"name\":\"Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDEzNiMzODM4MTg3IzIwMDg1OTY=\",\"datePublished\":\"2020-11-23T14:03:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDEzNiMzODM4MTg3IzIwMDg1OTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDEzNiMzODM4MTg3IzIwMDg1OTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials - Market Newsdesk","og_description":"BOSTON and DURHAM, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced a strategic partnership between its Early Phase Clinical Unit (EPCU) in Berlin, Germany and Clinical Trial Center (CTC) North, a full-service CRO located at the University Medical Center Hamburg-Eppendorf (UKE). The strategic collaboration supports the high demand for and continuation of Early Phase clinical studies during the COVID-19 pandemic, enabling the optimal use of resources and providing additional bed capacity for healthy volunteers and patients ensuring early phase research can continue. One central point of the collaboration will be the roll-out and implementation of Parexel\u2019s &hellip; Continue reading \"Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T14:03:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEzNiMzODM4MTg3IzIwMDg1OTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials","datePublished":"2020-11-23T14:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/"},"wordCount":672,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEzNiMzODM4MTg3IzIwMDg1OTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/","name":"Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEzNiMzODM4MTg3IzIwMDg1OTY=","datePublished":"2020-11-23T14:03:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEzNiMzODM4MTg3IzIwMDg1OTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEzNiMzODM4MTg3IzIwMDg1OTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parexel-partners-with-ctc-north-to-increase-research-capacity-for-delivery-of-early-phase-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386838"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386838\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386838"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}